Introduction
============

To date, randomized trials have demonstrated similar survival rates between patients with primary breast cancer who underwent breast-conserving treatment (BCT) or modified radical mastectomy (MRM) [@B1], [@B2]. However, recent tumor registry data have suggested the potential superiority of BCS when combined with RT [@B3], consistent with the results of a Chinese study [@B4]. Data regarding the addition of neoadjuvant chemotherapy (NAC) have been less consistent. One study found that tumor downsizing via NAC was associated with a higher risk of local recurrence (LR) after BCT [@B5].

In this report, we summarize the results of a long-term follow-up analysis of patients who underwent BCT for primary breast cancer at a single institution. Briefly, this analysis focused on the outcomes of LR, ipsilateral breast tumor recurrence (IBTR), distant disease-free survival (DDFS), and disease-free survival (DFS). Furthermore, we aimed to quantify the associations of clinical and pathological characteristics with LR among Chinese women with primary breast cancer who underwent BCT.

Methods
=======

Patient characteristics
-----------------------

Data on 6323 women with primary breast cancer who underwent BCT or MRM between December 1999 and April 2011 were obtained from a database created and managed by our hospital. Women who were diagnosed with primary invasive breast cancer and underwent BCS followed by radiotherapy were included in this study.

The patients\' clinical, pathological, and treatment information was obtained from the database of the Breast Cancer Center, including the age at diagnosis, axillary lymph node spread, hormone receptor status, use of NAC, maximal tumor diameter, human epidermal growth factor receptor 2 (HER2) status, preoperative magnetic resonance imaging (MRI), date of surgery, and use of computed tomography (CT) information during boost field planning. We note that MRI has been used at our institution for the preoperative staging of the affected breast in women with newly diagnosed breast cancer since 2007.

Surgical procedures and adjuvant therapy
----------------------------------------

Ultrasound localization was used preoperatively to maximize the probability of complete tumor removal. Tumors were marked with skin tattoos prior to the administration of NAC. The closed-cavity surgical procedure included resection of the primary tumor with a surrounding normal tissue margin of at least 0.5-1.0 cm, which was determined according to the surgeon\'s observation and the results of intraoperative frozen section evaluations. Glandular reshaping was based on the ratio of breast size to tumor resection volume.

The operative specimens were oriented using 1-4 sutures marking the medial, lateral, superior, and inferior surfaces. Each separate, additional shaved margin was labeled with a suture at the new section. Shaved margins were obtained for all patients at the time of the original surgery. Each specimen was sliced into sections that were tangent to each labeled margin from the exterior of the tumor mass. If a positive margin was identified, additional tissue was excised during the same surgery according to the patient\'s surgical cavity, with the ultimate aim of obtaining a negative margin. The final margin status was determined by examining permanent paraffin-embedded sections shaved from the interior of the frozen section, after which no additional margin slices were obtained from the residual specimen. Furthermore, sentinel lymph node biopsy with a ^99m^Tc-labeled rituximab tracer was introduced at our institution in 2005. Patients with positive sentinel lymph nodes underwent complete staging with axillary lymph node dissection.

In addition to surgical excision of the primary tumor with a negative margin, all patients were administered radiotherapy using tangential fields directed at the intact breast. Before 2007 at Peking University Cancer Hospital, surgical scar was used to identify the tumor bed to determine the boost area. Since 2007, CT-based treatment planning for patients with breast cancer has been routinely applied and used to define the boost fields.

The principles of adjuvant chemotherapy (or NAC) and adjuvant hormonal therapy was consistent with the guidelines of the National Comprehensive Cancer Network and St. Gallen. NAC was defined as at least two cycles of preoperative chemotherapy, which comprised anthracycline- and/or taxane-based regimens.

Recurrence and distant metastasis
---------------------------------

The primary endpoints of this study were LR and IBTR. The secondary endpoints were DDFS and DFS. All patients underwent annual mammography screenings, as well as ultrasonography of the bilateral breasts (or the remaining breast in cases of total mastectomy) and lymphatic regions every 6 months for 5 years postoperatively and annually thereafter. Other diagnostic studies were performed at the discretion of the referring physician. An IBTR was classified as a definite LR if it was located within 3 cm of the original primary tumor bed (i.e., within the same quadrant), was determined to be of the same histological type, and had the same or a higher grade. DDFS was defined as the time interval from surgery to distant metastases, while DFS was defined as the time interval from surgery to local, regional, or distant treatment failure.

Statistical analysis
--------------------

Patient characteristics were compared between subtypes using the chi-square test. Survival probabilities were estimated using the Kaplan-Meier method. Patient and tumor characteristics were individually analyzed using the log-rank test to determine the effect of each variable. A Cox proportional hazards regression was used to assess the independent associations of several variables with LR, IBTR, DDFS, and DFS. Hazard ratios (HRs) and their 95% confidence intervals (95% CIs) were estimated using a Cox model with a backward stepwise method. All reported *P* values were two-sided, and a value of \<0.05 was considered statistically significant. All statistical analyses were performed using SPSS 17.0 (IBM, Armonk, NY, USA).

Results
=======

Between December 1999 and April 2011, a total of 2028 patients (32.1%) with invasive breast cancer who underwent BCT were enrolled; among them, postoperative follow-up records were unavailable for 24 patients. The median follow-up duration after definitive surgery was 95 months (range, 5-193 months). However, 103 patients (5.0%) were lost to follow-up and were recorded as having a follow-up duration of \<60 months. The 8-year LR, IBTR, DDFS, and DFS rates were 2.6% (95% CI, 1.9-3.3%), 3.0% (95% CI, 2.3-3.7%), 93.7% (95% CI, 92.6-94.8%), and 91.3% (95% CI, 90.0-92.6%), respectively. Table [1](#T1){ref-type="table"} presents the clinical characteristics of the patient cohort.

Local control
-------------

The clinical and pathological factors found to associate with the 8-year LR rate are presented in Table [2](#T2){ref-type="table"}. Lymph node involvement, a HER2-positive status, and the use of CT information during boost field planning were significantly associated with LR according to both log-rank tests and a Cox multivariate analysis (Figs. [1](#F1){ref-type="fig"}, 2, 3). Specifically, women with a HER2-positive status had a higher risk of LR, compared to those with a HER2-negative status (HR of HER2-positive vs. -negative, 1.67; 95% CI, 1.24-2.26; *P* = 0.001). Furthermore, the use of CT for tumor bed identification during boost field planning was associated with a significant improvement in the local control rate, compared to the use of surgical scars (HR of CT vs. surgical scar, 0.24; 95% CI, 0.12-0.47; *P* \<0.001) (Table [2](#T2){ref-type="table"}).

The 8-year LR rates were 5.1% (95% CI, 3.6-6.4%) during the period 1999-2007 and 0.8% (95% CI, 0.3-1.3%) during the period 2007-2011. The data on 8-year LR rates by treatment year were 5.6% (95% CI, 3.5-7.7%) during the period 1999-2005, 5.5% (95% CI, 2.6-8.4%) during 2006, 0.7% (95% CI, 0-1.6%) during 2007, 1.4% (95% CI, 0.1-2.7%) during 2008, 1.1% (95% CI, 0-2.2%) during 2009 and 1.7% (95% CI, 0.4-3.0%) during 2010.

We also performed univariate and multivariate analyses of various clinical, pathological, and treatment factors to identify predictors of IBTR. Lymph node involvement, a HER2-positive status, and the use of CT information during boost field planning were found to be independent predictors of IBTR (Table [3](#T3){ref-type="table"}). However, age and the NAC were not independent predictors of either LR or IBTR.

DDFS and DFS
------------

The above-mentioned multivariate analysis also identified the nodal status, age at diagnosis, and NAC as factors significantly affecting the 8-year DDFS rate (Table [4](#T4){ref-type="table"}). Although the age at diagnosis was not an independent predictor of LR, it was identified as an independent predictor of DDFS in both univariate and multivariate analyses (HR of \>40 vs. ≤40 years, 0.60; 95% CI, 0.41-0.90; *P* = 0.013). Finally, the age at diagnosis, T stage, lymph node involvement, HER2-positive status, and use of CT information during boost field planning were identified as independent predictors of DFS (Table [5](#T5){ref-type="table"}).

Discussion
==========

In this study of the associations of BCT with 8-year outcome rates determined using the Kaplan-Meier method, we determined a LR rate of 2.6% and IBTR rate of 3.0%, which are consistent with those reported in other contemporary series [@B1], [@B2], [@B6]. Furthermore, we found that the use of CT data during boost field planning significantly reduced the risk of LR. We observed a 5-year LR rate of 0.7% between 2007 and 2011, which was superior to the results reported by the TARGIT-A trial (5-year risk of conserved breast LR in the control group = 1.3% \[0.7%-2.5%\]) [@B7]. Additionally, we observed a decreasing trend in the LR rate after BCT during the study period; this rate remained at 0.7% annually for patients treated during 1999-2007 and decreased to 0.1% annually during the period 2007-2011. LR rate decreased significantly on 2007. The rates were stable within post-2007 groups. Interestingly, 32.1% of patients in this study received BCT. This is among the highest rates of BCT among studies of Chinese patients.

In a previous study, radiotherapy after BCS not only substantially reduced the risk of recurrence, but also moderately reduced the risk of death from breast cancer [@B6]. However, postoperative breast changes and remodeling present a challenge to the localization of the tumor bed. Accordingly, many centers currently use CT-based planning for breast radiotherapy [@B8]-[@B10]. CT scans also provide information regarding the placement of the boost field. In most cases, the excision cavity can be visualized. The depth, therefore the electron beam energy, can be determined. This study further confirmed a significant association of the use of CT information during boost field planning with LR. In this study, volume replacement techniques based on glandular reshaping were applied to patients to obtain better cosmetic outcomes. The use of the surgical scar to determine the tumor bed and, therefore, the boost field may yield poor outcomes, as this can result in geographical misses and lead to increased local failure rates. Although a European Organisation for Research and Treatment of Cancer (EORTC) trial reported a decreased risk of IBTR in patients who received the boost dose, no differences in survival were observed between patients who received and did not receive a boost of 16 Gy after whole-breast irradiation [@B11]. In the present study, we found that the use of CT information during boost field planning did not lead to a reduction in distant recurrence. The findings of an earlier Early Breast Cancer Trialists\' Collaborative Group (EBCTCG) meta-analysis showed that unless the difference in LR was 10%, there was no difference in OS [@B6]. The findings of this report are consistent with the EBCTCG. 37.4% of patients in the present study were node positive. We note that the EBCTCG trial specifically reported the survival benefit of radiotherapy in node-positive patients.

NAC is widely accepted as a treatment for advanced operable breast cancer, as it can reduce the size of the primary tumor and therefore increase the likelihood of successfully completing a BCS in patients advised to undergo a mastectomy [@B12], [@B13]. Two large randomized trials, National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 and EORTC 10902, compared preoperative chemotherapy with postoperative chemotherapy in patients with operable breast cancer. Both trials reported equivalent survival rates between the arms, as well as increased rates of BCS performance following preoperative chemotherapy [@B12], [@B13]. In our analysis, we did not identify NAC as an independent predictor of LR. Patients with a more advanced clinical T stage or a node-positive status at diagnosis were generally encouraged by oncologists to receive NAC and were considered to have a worse biologic entity. We further found that neoadjuvant treatment was associated with a higher relative risk of DDFS, compared to adjuvant treatment. However, we cannot explain the effect of a pathological response on LR in this study because the pathological response after NAC was not evaluated. Mittendorf et al. reported no difference in the LR rates between patients undergoing surgery first vs. those treated with NAC [@B14], while a meta-analysis by Mieog et al. demonstrated a non-significant increase in the local relapse rate in the NAC group, compared with the adjuvant therapy group [@B15]. A recent study reported a higher LR rate among patients who underwent NAC than among those treated with surgery first, as well as a potential association of tumor downstaging by NAC with an increased risk of LR after BCS [@B5]. However, the meta-analysis was biased by the inclusion of patients who did not receive optimal local treatment after NAC [@B5]. Tumor resection with a clear margin and an acceptable cosmetic result requires sufficient shrinkage of the tumor via NAC. However, the current methods used to assess tumor shrinkage patterns preoperatively are inadequate. In the present study, the entire area of the original primary tumor was resected after NAC, although this practice is not considered necessary by the St. Gallen Expert Consensus Panel [@B16].

Many previous studies on BCT have identified an increased risk of local relapse in younger women, compared with older women [@B17], [@B18]. However, limited data are available from Chinese women. Our findings demonstrated showed that the rate of local relapse after BCT did not differ between young (≤40 years) and older (\>40 years) women, and similar results were obtained from the comparisons of other dichotomized age groups. These findings are not consistent with those of earlier trials [@B6], [@B17], [@B18].

In previous studies, the administration of anti-HER2 therapy has yielded significant survival advantages when administered to early breast cancer patients with or after chemotherapy, compared to observation alone [@B19], [@B20]. In the present study, however, only a few patients could afford trastuzumab treatment. Therefore, a HER2-positive status remained an independent predictor of LR and IBTR.

A previous report found that the inclusion of MRI in a preoperative assessment did not improve surgical treatment outcomes or reduce the risk of re-excision [@B21], and a meta-analysis demonstrated that preoperative MRI for breast cancer staging did not reduce the risk of LR [@B22]. At our center, we first integrated MRI into practice for the staging of newly diagnosed breast cancer in January 2007. Consistent with earlier reports, the present study found no association of preoperative MRI with a reduced risk of LR or an improved DFS. We note that MRI is mainly used to determine the conversion from BCS to mastectomy; in other words, this imaging modality increases the risk of a more intensive therapeutic surgery [@B22]-[@B24]. Although MRI can detect previously unrecognized but pathologically confirmed cancer deposits, these lesions may be biologically and clinically irrelevant in a patient who is expected to undergo standard excision and breast irradiation.

Veronesi et al. reported that the characteristics of true recurrences (TR) were consistent with the regrowth of malignant cells not removed by surgery or killed by radiotherapy [@B25]. According to previous studies, the locations of the first and second tumors, histological subtypes and time to relapse were used to classify TR or new primary breast cancers (NP) [@B26]. Some studies have suggested an association of TR with reduced survival relative to NP [@B26]- [@B29]. Some molecular techniques such as DNA fingerprinting, loss of heterozygosity patterning, or allelic imbalance profiling have been used to distinguish NP from TR [@B30]. However, the classifications for these techniques have not been standardized.

There are several limitations in our study. First, a retrospective study has inherent bias and weakness. This study showed a non-significant increase in the local relapse rate in the NAC group and was unable to prove equivalent LR adequately. Second, CT-guidance was one of factors improving result, and other treatment factors may be not concerned in this retrospective study. Third, detailed data about extent or frequency of re-shaping were not available which were rarely recorded in previous operation notes. It is possible that the group for whom CT is useful is restricted to those undergoing re-shaping. We will improve the operation notes and do further research about this issue in future.

In conclusion, this retrospective study indicates that the use of CT information during boost field planning could reduce the risk of LR in patients undergoing BCT. However, the administration of NAC vs. adjuvant treatment did not significantly affect LR. Moreover, BCT is effective for local tumor control when performed in younger Chinese patients (≤40 years old).
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###### 

Patient characteristics

                               Patients        
  ---------------------------- --------------- -------------
  Age at diagnosis(years)      ≤40             515(25.7%)
  \>40                         1489(74.3%)     
  Size (cm)                    ≤2              1195(59.6%)
  \>2                          809(40.4%)      
  Hormone receptor             Negative        469(23.4%)
  Positive                     1470(73.4%)     
  unknown                      65(3.2%)        
  Axillary lymph node status   Negative        750(37.4%)
  Positive                     1254(62.6%)     
  Her-2 status                 Negative        1489(74.3%)
  Positive                     271(13.5%)      
  unknown                      244(12.2%)      
  Neoadjuvant chemotherapy     Yes             1079(53.8%)
  No                           925(46.2%)      
  Boost design method          Surgical scar   699(34.9%)
  CT-bed                       1305(65.1%)     
  Year of surgical             1999-2007.1.1   752(37.5%)
  2007-                        1252(62.5%)     
  preoperative MRI             No              1045(52.1%)
  Yes                          959(47.9%)      

###### 

Univariate and multivariable analysis for local recurrence

  Factors                       Univariate analysis             Multivariate analysis                     
  -------------------------- -- --------------------- --------- ----------------------- ----------------- ---------
  Age (years)                                                                                             
  ≤40                           3.2%±1.5%             0.173                             1                 0.292
  \>40                          2.3%±0.7%             ---                               0.72(0.39-1.32)   ---
  Size (cm)                                                                                               
  ≤2                            1.8%±0.7%             0.115                             1                 0.562
  \>2                           3.7%±1.3%             ---                               1.19(0.66-2.13)   ---
  Hormone receptor                                                                                        
  Negative                      3.7%±1.7%             0.070                             1                 0.519
  Positive                      2.3%±0.7%             ---                               0.82(0.44-1.51)   ---
  Axillary lymph node                                                                                     
  Negative                      1.4%±0.7%             \<0.001                           1                 0.006
  Positive                      4.5%±1.5%             ---                               2.27(1.27-4.01)   ---
  Her-2 status                                                                                            
  Negative                      2.3%±0.7%             \<0.001                           1                 0.001
  Positive                      6.5%±2.9%             ---                               1.67(1.24-2.26)   ---
  Neoadjuvant chemotherapy                                                                                
  Yes                           3.4%±1.1%             0.012                             1                 0.157
  No                            1.6%±0.9%             ---                               0.63(0.33-1.19)   ---
  Boost design method                                                                                     
  Surgical scar                 5.4%±1.7%             \<0.001                           1                 \<0.001
  CT-bed                        0.8%±0.5%             ---                               0.24(0.12-0.47)   ---
  Preoperative MRI                                                                                        
  Yes                           1.6%±0.7%             0.266                             1                 0.275
  No                            2.9%±0.9%             ---                               1.46(0.73-2.92)   ---

^\*^ *P* \<0.05 is deemed statistically significant (log-rank test); ^\*\*^ *HR*: hazard ratio; \*\*\**P* \<0.1 is deemed statistically significant.

###### 

Univariate and multivariable analysis for ipsilateral breast tumor recurrence (IBTR)

  Factors                       Univariate analysis             Multivariate analysis                     
  -------------------------- -- --------------------- --------- ----------------------- ----------------- ---------
  Age (years)                                                                                             
  ≤40                           3.8%±1.7%             0.182                             1                 0.206
  \>40                          2.8%±0.9%             ---                               0.70(0.41-1.21)   ---
  Size (cm)                                                                                               
  ≤2                            2.0%±0.7%             0.020                             1                 0.101
  \>2                           4.6%±1.5%             ---                               1.53(0.91-2.55)   ---
  Hormone receptor                                                                                        
  Negative                      4.6%±1.9%             0.102                             1                 0.277
  Positive                      2.9%±0.9%             ---                               0.74(0.43-1.27)   ---
  Axillary lymph node                                                                                     
  Negative                      1.6%±0.7%             \<0.001                           1                 0.002
  Positive                      5.4%±1.7%             ---                               2.29(1.36-3.86)   ---
  Her-2 status                                                                                            
  Negative                      2.8%±0.9%             0.001                             1                 0.002
  Positive                      6.0%±3.1%             ---                               1.56(1.18-2.05)   ---
  Neoadjuvant chemotherapy                                                                                
  Yes                           3.8%±1.1%             0.013                             1                 0.484
  No                            2.1%±0.9%             ---                               0.80(0.44-1.46)   ---
  Boost design method                                                                                     
  Surgical scar                 6.1%±1.7%             \<0.001                           1                 \<0.001
  CT-bed                        1.1%±0.5%             ---                               0.34(0.19-0.61)   ---
  Preoperative MRI                                                                                        
  Yes                           2.8%±1.1%             0.368                             1                 0.362
  No                            3.3%±1.1%             ---                               1.33(0.71-2.49)   ---

^\*^ *P* \<0.05 is deemed statistically significant (log-rank test); ^\*\*^ *HR:* hazard ratio; \*\*\**P* \<0.1 is deemed statistically significant.

###### 

Univariate and multivariable analysis for distant disease-free survival (DDFS)

  Factors                       Univariate analysis             Multivariate analysis                     
  -------------------------- -- --------------------- --------- ----------------------- ----------------- ---------
  Age (years)                                                                                             
  ≤40                           90.4%±2.7%            \<0.001                           1                 0.013
  \>40                          94.9%±1.1%            ---                               0.60(0.41-0.90)   ---
  Axillary lymph node                                                                                     
  Negative                      96.7%±0.9%            \<0.001                           1                 \<0.001
  Positive                      88.9%±2.3%            ---                               3.12(2.05-4.72)   ---
  Neoadjuvant chemotherapy                                                                                
  Yes                           92.0%±1.7%            \<0.001                           1                 0.072
  No                            95.9%±1.3%            ---                               0.67(0.43-1.03)   ---

^\*^ *P* \<0.05 is deemed statistically significant (log-rank test); ^\*\*^ *HR*: hazard ratio; \*\*\**P* \<0.1 is deemed statistically significant.

###### 

Univariate and multivariable analysis for disease-free survival (DFS)

  Factors                  Univariate analysis             Multivariate analysis                      
  --------------------- -- --------------------- --------- ----------------------- ------------------ ---------
  Age (years)                                                                                         
  ≤40                      88.0%±2.9%            0.001                             1                  0.016
  \>40                     92.5%±1.3%            ---                               0.66(0.47-0.92)    ---
  Size (cm)                                                                                           
  ≤2                       93.9%±1.3%            \<0.001                           1                  0.006
  \>2                      87.5%±2.3%            ---                               1.56(1.13-2.15)    ---
  Axillary lymph node                                                                                 
  Negative                 95.2%±1.1%            \<0.001                           1                  \<0.001
  Positive                 85.0%±2.7%            ---                               2.69(1.93-3.76)    ---
  Her-2 status                                                                                        
  Negative                 91.7%±1.5%            0.013                             1                  0.011
  Positive                 87.8%±4.1%            ---                               1.28 (1.05-1.54)   ---
  Boost design method                                                                                 
  Surgical scar            87.3%±2.5%            \<0.001                           1                  0.010
  CT-bed                   93.8%±1.3%            ---                               0.65(0.47-0.90)    ---

^\*^ *P* \<0.05 is deemed statistically significant (log-rank test); ^\*\*^ *HR*: hazard ratio; \*\*\**P* \<0.1 is deemed statistically significant.
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